SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that sports-event contracts are subject to state gambling oversight was viewed as a regulatory win for DraftKings, potentially weakening Kalshi and other prediction-market competitors. Traders remain divided over whether the decision will materially improve DraftKings long-term margins and market share, given ongoing legal challenges, competition, and promotional spending.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

A sharp post-earnings selloff and uncertainty around the failed or contested Salad and Go site acquisition have driven attention to Dutch Bros, with traders also debating valuation, potential dilution, and weaker consumer spending. Bulls view the decline as an oversold buying opportunity supported by continued store expansion and busy locations, while bears argue the high valuation and macro pressure leave room for further downside.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of Fayuvi (UX111), the first approved treatment for Sanfilippo syndrome type A, is driving attention, along with the associated Priority Review Voucher and planned commercial launch. Traders are broadly bullish and discussing a potential rerating, short covering, or buyout, while skeptics point to the small eligible patient population, one-time treatment model, commercialization risks, and Ultragenyxs cash burn as reasons the initial reaction has been muted.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Reported purchases by Helus Pharma executives and founders are driving bullish attention, alongside anticipation of Phase 3 HLP003 data expected in Q4 2026. Traders remain divided between viewing the buying and new leadership as confidence signals and worrying about dilution, profit-taking, and clinical-readout risk.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

A new $1 billion at-the-market equity offering, following prior share issuance and recurring founder/insider sales, is driving attention and fueling dilution concerns. Bulls argue the financing supports Oklos advanced-nuclear and AI data-center opportunity, while traders debate a short-covering rebound versus continued selling pressure; potential FERC news remains speculative.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

The Federal Reserves interest-rate hike is driving discussion, with traders debating whether higher funding costs and weaker lending demand will pressure SoFi or whether the move was already priced in and could benefit its banking spread. Sentiment is broadly frustrated by the stocks underperformance, dilution concerns and criticism of CEO Anthony Noto, despite some bulls pointing to continued growth and upcoming earnings.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

A weaker quarterly report and reduced full-year outlook have driven attention, with traders focusing on BetterHelps faster-than-expected decline in cash-pay demand during its shift to insurance and a shortage of credentialed providers. The community is split between criticism of managements execution and communication versus optimism that the insurance transition, Teladoc One, and integrated-care growth could improve results over time.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

A Barclays upgrade and positive physician-survey commentary have reinforced optimism around Lifileucel, while traders are positioning for revised guidance and an upcoming IOV-LUN-202 non-small-cell lung cancer update. The community is broadly bullish, though some attribute the volatile pullbacks to profit-taking, options positioning, and possible short covering.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves proposed convertible-notes financing and potential ATM share sales have triggered heavy dilution and leverage concerns, reversing an earlier rally and weighing on the broader AI-infrastructure group. Traders are debating whether the funding is necessary to expand into strong compute demand and growing commitments or signals worsening capital needs and shareholder dilution.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant selling pressure driven by investor concerns over insider stock sales, upcoming lock-up expirations, and a broader market risk-off sentiment toward AI growth stocks. While some traders are bullish on the company's wafer-scale AI infrastructure and partnerships, others are concerned about overvaluation and the potential for increased volatility as more shares become eligible for sale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


88bgbnet

88bgbnet